Finch Therapeutics Group, Inc.

finchtherapeutics.com

No Longer Reporting

The company has not filed an annual or quarterly report since its Q2 FY2024 10-Q, filed Aug 13, 2024. Its latest SEC filing is a 15-12G from Nov 12, 2024.

The sections below describe the company as of the FY2023 annual report.

What Did They Do?

Licenses microbiome technology to collaboration partners, pursues patent rights against alleged infringers, and works with academic collaborators on selected microbiome candidates.

How Did They Make Money?

Collaboration and license partners pay for research services and technology rights over the work period; Finch also receives royalties tied to sales of fecal microbiota transplantation materials.

FY2023 revenue

Who Were Their Customers?

Partners contract with Finch under collaboration and license agreements for research and technology rights; OpenBiome's sales of fecal microbiota transplantation materials also generate royalty payments to Finch.

Did Revenues Turn Into Profits?

No. It lost $74.8M in FY2023.

Operating income, FY2023

−78375% of revenue

▼ −27% (Loss) vs FY2022 (−$115.6M, −13425%)

Net income, FY2023

−69864% of revenue

▼ −35% (Loss) vs FY2022 (−$114.6M, −13315%)

Free cash flow, FY2023

−29444% of revenue

▼ −59% (Loss) vs FY2022 (−$77M, −8947%)

How Were They Changing?

Since the FY2023 annual report

Latest quarter: Q2 FY2024, the three months to Jun 30, 2024

Revenue: vs $0 in Q2 FY2023
Net income: ▼ −30% (Loss); vs −$7M in Q2 FY2023

Oct 21, 2024 Announced plans to delist shares from Nasdaq and end SEC registration The company expects its shares to continue trading over the counter after delisting.
Aug 12, 2024 Jury finds Ferring infringed patents and awards royalties The verdict included an upfront payment and running royalties; Ferring is expected to seek post-trial motions and appeal.

Comments